The National Primary Health Care Development Agency (NPHCDA) has said that it is aware of precautionary concerns that has been raised regarding one specific batch of the AstraZeneca vaccine, namely ABV5300.
The Agency made this known through a press statement released last week and signed by it’s Head of Public Relations Unit, Mohammad Ohitoto.
TheFact Nigeria gathered that Nigeria did not receive any doses from the batch of vaccines under contention.
“We understand that investigations are being conducted to determine if the batch is in any way linked to an observed side effect.
“We are satisfied that the clinical evidence indicates the Oxford-AstraZeneca vaccine to be safe and effective.
“Our assessment is in line with countries such as Spain and the UK who have indicated that they will continue to administer the vaccine, because it remains an important tool to protect against COVID-19.” He explained
Vaccinations in Nigeria started earlier this month and we have not observed any similar adverse reactions. All side effects reported by those who have been administered the vaccine have been mild.
He emphasised that, the safety of vaccines delivered to Nigeria is paramount to the Presidential Task Force on COVID-19. For this reason, it has enhanced multi-sectoral collaboration among stakeholders and technical entities such as the FMOH, NPHCDA, NAFDAC, WHO and UNICEF whose cooperation ensures the highest global standards are met for vaccines delivered to Nigeria before they are distributed to Nigerians. Clear, rigorous protocols are being followed to safeguard the health of Nigerians.
“We are continuing to monitor the developments regarding ABV5300 batch and will share further information as it becomes available.” He said
He also encouraged Nigerians who are among those being prioritized in the current phase to continue their confidence and enthusiasm “for our vitally important national vaccine program”.